Comparison of Mendeliome exome capture kits for use in clinical diagnostics
Abstract Next generation sequencing has disrupted genetic testing, allowing far more scope in the tests applied. The appropriate sections of the genome to be tested can now be readily selected, from single mutations to whole-genome sequencing. One product offering within this spectrum are focused ex...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-60215-y |
id |
doaj-d0ff4ef14c084a28b6648af15e4ab6eb |
---|---|
record_format |
Article |
spelling |
doaj-d0ff4ef14c084a28b6648af15e4ab6eb2021-02-23T09:31:31ZengNature Publishing GroupScientific Reports2045-23222020-02-011011710.1038/s41598-020-60215-yComparison of Mendeliome exome capture kits for use in clinical diagnosticsReuben J. Pengelly0Daniel Ward1David Hunt2Christopher Mattocks3Sarah Ennis4Human Genetics and Genomic Medicine, Faculty of Medicine, University of SouthamptonNational Genetics Reference Laboratory (Wessex), Salisbury District HospitalWessex Clinical Genetics Service, Princess Anne HospitalNational Genetics Reference Laboratory (Wessex), Salisbury District HospitalHuman Genetics and Genomic Medicine, Faculty of Medicine, University of SouthamptonAbstract Next generation sequencing has disrupted genetic testing, allowing far more scope in the tests applied. The appropriate sections of the genome to be tested can now be readily selected, from single mutations to whole-genome sequencing. One product offering within this spectrum are focused exomes, targeting ~5,000 genes know to be implicated in human disease. These are designed to offer a flexible platform offering high diagnostic yield with a reduction in sequencing requirement compared to whole exome sequencing. Here, we have undertaken sequencing of control DNA samples and compare two kits, the Illumina TruSight One and the Agilent SureSelect Focused Exome. Characteristics of the kits are comprehensively evaluated. Despite the larger design region of the Agilent kit, we find that the Illumina kit performs better in terms of gene coverage, as well as coverage of clinically relevant loci. We provide exhaustive coverage statistics for each kit to aid the assessment of their suitability and provide read data for control DNA samples to allow for bioinformatic benchmarking by users developing pipelines for these data.https://doi.org/10.1038/s41598-020-60215-y |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Reuben J. Pengelly Daniel Ward David Hunt Christopher Mattocks Sarah Ennis |
spellingShingle |
Reuben J. Pengelly Daniel Ward David Hunt Christopher Mattocks Sarah Ennis Comparison of Mendeliome exome capture kits for use in clinical diagnostics Scientific Reports |
author_facet |
Reuben J. Pengelly Daniel Ward David Hunt Christopher Mattocks Sarah Ennis |
author_sort |
Reuben J. Pengelly |
title |
Comparison of Mendeliome exome capture kits for use in clinical diagnostics |
title_short |
Comparison of Mendeliome exome capture kits for use in clinical diagnostics |
title_full |
Comparison of Mendeliome exome capture kits for use in clinical diagnostics |
title_fullStr |
Comparison of Mendeliome exome capture kits for use in clinical diagnostics |
title_full_unstemmed |
Comparison of Mendeliome exome capture kits for use in clinical diagnostics |
title_sort |
comparison of mendeliome exome capture kits for use in clinical diagnostics |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2020-02-01 |
description |
Abstract Next generation sequencing has disrupted genetic testing, allowing far more scope in the tests applied. The appropriate sections of the genome to be tested can now be readily selected, from single mutations to whole-genome sequencing. One product offering within this spectrum are focused exomes, targeting ~5,000 genes know to be implicated in human disease. These are designed to offer a flexible platform offering high diagnostic yield with a reduction in sequencing requirement compared to whole exome sequencing. Here, we have undertaken sequencing of control DNA samples and compare two kits, the Illumina TruSight One and the Agilent SureSelect Focused Exome. Characteristics of the kits are comprehensively evaluated. Despite the larger design region of the Agilent kit, we find that the Illumina kit performs better in terms of gene coverage, as well as coverage of clinically relevant loci. We provide exhaustive coverage statistics for each kit to aid the assessment of their suitability and provide read data for control DNA samples to allow for bioinformatic benchmarking by users developing pipelines for these data. |
url |
https://doi.org/10.1038/s41598-020-60215-y |
work_keys_str_mv |
AT reubenjpengelly comparisonofmendeliomeexomecapturekitsforuseinclinicaldiagnostics AT danielward comparisonofmendeliomeexomecapturekitsforuseinclinicaldiagnostics AT davidhunt comparisonofmendeliomeexomecapturekitsforuseinclinicaldiagnostics AT christophermattocks comparisonofmendeliomeexomecapturekitsforuseinclinicaldiagnostics AT sarahennis comparisonofmendeliomeexomecapturekitsforuseinclinicaldiagnostics |
_version_ |
1714850590382620672 |